



# Mark Sherman, MDCM, FRCPC, FNLA

Montreal VSL 6363 Transcanadienne, Suite 238, Ville Saint-Laurent, Quebec, H4T 1Z9, Canada Tel (514) 744-5620  
Montreal Glen 5325 Crowley Avenue, Suite 301, Montréal, Québec, H4A 2C6, Canada Tel (438) 802-4536

## CURRICULUM VITAE

### Education, Certification & Licenses

2019-2021	ICH-GCP Training	Syneos Health
2018	Fellow	National Lipid Association
2009	Diplomat	American Board of Clinical Lipidology
1993	Fellow, Endocrinology & Metabolism	Royal College of Physicians and Surgeons of Canada
1993	Certificate, Endocrinology	Quebec College of Physicians
1991	Certificate, Internal Medicine	Quebec College of Physicians
1991	Certificate, Internal Medicine	Royal College of Physicians Canada
Aug 1988	Licentiate of the Medical Council of Canada	Medical Council of Canada
1983-1987	MDCM	McGill University, Faculty of Medicine, Montréal QC
1982-1983	Med-P Programme	McGill University, Faculty of Medicine, Montréal QC
1980-1982	DEC/DCS	Vanier College, St. Laurent QC

### Internship & Residences

Jan 1991-Jan 1993	Residency, Endocrinology and Metabolism	McGill University, Montréal QC
Jul 1990-Jan 1991	Chief Resident, McGill University, Internal Medicine	Sir Mortimer B Davis-Jewish General Hospital, Montréal QC
Jul 1988- Jun 1990	Residency, McGill University, Internal Medicine	Sir Mortimer B Davis-Jewish General Hospital, Montréal QC
Jul 1987-Jun1988	Internship, McGill University, Internal Medicine	Sir Mortimer B Davis-Jewish General Hospital, Montréal QC

### Professional Activities

2018-Present	Publication Committee	Lipid Spin, National Lipid Association
2017-Present	Principal Investigator	LMC Clinical Research Inc.
2017-Present	Sub-Investigator	LMC Clinical Research Inc.
2017-Present	Associate Endocrinologist	LMC Diabetes & Endocrinology
2015-Present	Associate Investigator	MUHC Research Institute
Feb 2012-Present	Associate Professor (Clinical), Dept. Of Medicine	McGill University, Faculty of Medicine, Montréal QC
Jul 1999-Present	Associate Physician, Division of Endocrinology and Metabolism	Royal Victoria Hospital, Montréal QC
1997-Present	Director, Lipid Clinic	McGill University Health Centre, Montréal QC
2008-Present	Director, Metabolic Day Centre	Royal Victoria Hospital, Montréal QC
Jan 2012-Dec 2016	Interim Director, Division of Endocrinology (Dept of Medicine)	McGill and MUHC, Montréal QC
1997-1998	Assistant Director, Endocrinology and Metabolism Training	McGill University, Montréal QC
1993-Present	Director, Lipid Clinic	Royal Victoria Hospital, Montréal QC
Jan 1993-2012	Assistant Professor of Medicine	McGill University, Montréal QC
Jan 1993-1999	Assistant Physician, Division of Endocrinology and Metabolism	Royal Victoria Hospital, Montréal QC
Jan 1990-Jun1991	Locum	Mount Sinai Hospital Centre, Ste Agathe, QC & Cote St. Luc., QC

### Memberships

2014-Present	Associate Member, Division of Endocrinology and Metabolism	Jewish General Hospital, Montréal QC
1997-1998, 2008-Present	Member, Executive Committee, Division of Endocrinology and Metabolism	Royal Victoria Hospital
1997-2011	Endocrinology Representative, Diabetes Task Force	Royal Victoria Hospital/MUHC
1997	Member, Accreditation Committee, Endocrinology Division	Canadian Council on Health Services Accreditation
1993-Present	Member	Royal Victoria Hospital/MUHC Research Institute

### Publications

Robert-Halabi M, Ni J, Nguyen A, Dube M-P, Al Turki A, Sherman M, Thanassoulis G, Gregoire J, Tardif J-C, Huynh T. Long-Term Residual Risk and Predictors of Cardiovascular Disease in Individuals Taking Statins for Primary Prevention: Insights from the Cartagene Study. *Journal of the American College of Cardiology*, 2019, 73(9):1773. doi: 10.1016/S0735-1097(19)32379-4

Al Turki A, Marafi M, Dawas A, Dube M-P, Vieira L, **Sherman MH**, Gregoire J, Thanassoulis G, Tardif J-C, Huynh T. Meta-Analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes. *American Journal of Cardiology*, 2019, 124 (12), 1869-1875. <https://doi.org/10.1016/j.amjcard.2019.09.011>

George O, Tsoukas, Claudia Blais, Roxanne Gagnon, Denis Hamel, **Mark Sherman**, Natasha Garfield, Vidal Essebag, Thao Huynh. The Impact of Pharmacotherapy on Long-Term Survival and Stroke after Hospitalization for Atrial Fibrillation. *Journal Of The American College Of Cardiology* 65(10):A390 · March 2015 - doi: 10.1016/S0735-1097(15)60390-4

George Tsoukas, Claudia Blais, Roxanne Gagnon, Denis Hamel, **Mark Sherman**, Natasha Garfield, Vidal Essebag, Thao Huynh. Risks Of Long-Term Mortality And Major Adverse Cardio-Vascular Events Associated With Diabetes Mellitus In Patients Hospitalized For Atrial Fibrillation. *Journal Of The American College Of Cardiology* 65(10):A319 · March 2015 - doi: 10.1016/S0735-1097(15)60319-9

Samantha Hajna; Yan Kestens; Stella S Daskalopoulou; Lawrence Joseph; Benoit Thierry; **Mark Sherman**; Luc Trudeau; Rémi Rabasa-Lhoret; Leslie Meissner; Simon L. Bacon; Lise Gauvin; Nancy A. Ross; Kaberi Dasgupta; Neighbourhood Walkability And Home Neighbourhood-Based Physical Activity: An Observational Study Of Adults With Type 2 Diabetes. *BMC Public Health - BMC Public Health*. 2016, 16:957 – doi:10.1186/s12889-016-3603-y

Dasgupta K, Rosenberg E, Joseph L, Trudeau L, Bacon SL, Chan D, **Sherman M**, Rabasa-Lhoret R, Daskalopoulou SS for the SMARTER trial group, Physician step prescription and monitoring to improve ARTERial health (SMARTER): a randomized controlled trial in type 2 diabetes and hypertension. *Diabetes Obes Metab*. 2017 Jan 11. doi: 10.1111/dom.12874. [Epub ahead of print]

Dasgupta K, Rosenberg E, Joseph L, Trudeau L, Chan D, **Sherman M**, Rabasa-Lhoret R, Daskalopoulou SS. Carotid femoral pulse wave velocity in type 2 diabetes and hypertension: capturing arterial health effects of step counts. *J Hypertens*. 2017 Jan 27. doi: 10.1097/HJH.0000000000001277. [Epub ahead of print] PubMed PMID: 28129250

### Clinical Trials & Research Activities

2010-2020 SMARTER (MUHC), D-STAT-2010 (MUHC), CAVEAT (Bayer), CHOIR (Bayer), ACCORD (NIH), A2581091 (Pfizer), A5091043 (Pfizer), LANTU\_C\_00579 (Sanofi), EFC6014 (Sanofi), D1680C00003 (AstraZeneca), MK-0431-082 (Merck), ACCORDION (NHLBI), MK-3102 (Merck), D5551C00003 (AstraZeneca), AMR-01-01-0019 (Amarin Pharma), H9X-MC-GBDJ (Eli Lilly), EFC126126 (Sanofi), MYL-1501D-3003 (Mylan Inc.), 1218-0022 (Boehringer Ingelheim), 17530 (Bayer), 16244 (Bayer), ISI 681257 (Ionis Pharmaceuticals Inc.), EFC14875 (Sanofi), 703802-C02 (Akcea), EFC14837 (Sanofi), NN1250-4419 (Novo Nordisk), NN9536-4374 (Novo Nordisk), NN9535-4428 (Novo Nordisk), EFC14828 (Sanofi), I8F-MC-GPGM (Eli Lilly), LPS15544 (Sanofi), NN9535-4352 (Novo Nordisk), K-877-302 (KOWA), EFC14868 (Sanofi), I8B-MC-ITRO (Lilly), etc.

>12 Publications, >48 Research Activities, >12 Abstracts/Posters